Greentrial AI: AI for Sustainable Clinical Trial Logistics

Abstract

The clinical trials industry faces mounting pressure to address its environmental impact, with Phase III trials generating up to 15,000 metric tons of CO?e. Industry stakeholders have committed to achieving 90% greenhouse gas (GHG) reduction by 2040, necessitating transformative approaches to trial logistics. This study develops and validates the GreenTrial AI ecosystem framework, which integrates artificial intelligence across all clinical trial logistics domains to optimize sustainability outcomes while maintaining operational efficiency and regulatory compliance. A multi-stakeholder framework development process was employed, incorporating life cycle assessment (LCA) methodology for carbon footprint quantification, return-on investment modeling for economic viability analysis, and comprehensive regulatory landscape assessment across global jurisdictions to quantitatively assess logistics sustainability across factors like fuel consumption, emission intensity, and packaging waste. A new Green Logistics Index (GLI) is presented. This paper presents the GreenTrial AI framework, which uses artificial intelligence (AI) to promote sustainability in clinical trial logistics, in accordance with the World Health Organization's Global Clinical Trials Forum. The GreenTrial AI framework indicates potential for 41-fold carbon reduction through optimized site selection and decentralized trial designs, 65?celeration in patient recruitment via AI- powered matching algorithms, and 30 50% waste reduction through predictive supply chain management. Integration of generative AI enables illustrative protocol optimization and adaptive trial designs that simultaneously enhance environmental and clinical outcomes.

Keywords

Sustainable clinical trials, Artificial intelligence, green logistics, carbon footprint, decentralized trials, regulatory frameworks.

Introduction

The figure outlines the anticipated regulatory evolution from 2025 to 2030, highlighting the parallel advancement of pharmaceutical, AI, and clinical trial regulations across global agencies. It underscores a growing emphasis on transparency, sustainability, patient-centricity, and ethical governance to support the safe and responsible integration of AI into clinical research.

Economic Impact: Patient Recruitment and Revenue Acceleration

1. Patient Recruitment Acceleration: AI-driven patient identification and recruitment platforms represent one of the largest economic impact domains in clinical trials. By leveraging real-world data, predictive analytics, and machine learning, these systems accelerate recruitment timelines by approximately 40%, avoiding $300,000–$800,000 in trial costs per study (Zhang et al., 2024; MedCity News, 2025).

Key drivers include: Reduced recruitment delays, Optimized site selection and Environmental co-benefits.

2. Revenue Acceleration: AI-enabled trial optimization also accelerates time-to-market, generating significant revenue impact. Overall development timelines can be reduced by 2–6 months, translating into $2–10 million additional revenue for blockbuster therapeutics (Pharmaceutical Technology, 2025). For high-value indications like oncology or rare diseases, daily revenues may exceed $100,000, meaning even modest timeline gains can yield eight-figure value creation (Liu et al., 2023).

Analytical mapping of existing platforms and Implementation Guide

Effective deployment of the GreenTrial AI Ecosystem depends on the strategic integration of artificial intelligence platforms, cloud infrastructure, digital health technologies, and sustainability measurement systems. To support adoption while minimizing disruption, GreenTrial AI follows a four-phase implementation roadmap designed to balance speed, scalability, and change management:

1. Foundation Phase – Digital readiness assessment, data harmonization, cloud migration, and sustainability baseline measurement.
2. PiIoT Phase – Targeted deployment of AI modules (recruitment, monitoring, or supply chain) in selected trials to validate performance and compliance.
3. Scale-Up Phase – Portfolio-wide expansion with integrated dashboards, automated reporting, and cross-functional training programs.
4. Optimization Phase – Continuous learning through AI feedback loops, advanced LCA modeling, and predictive sustainability analytics.

GreenTrial AI Technology Architecture

The GreenTrial AI technology architecture is built on three foundational principles: interoperability, cloud-native design, and compliance with established clinical data standards, particularly CDISC and HL7 FHIR. This standards-aligned approach enables seamless integration with existing clinical trial systems, such as CTMS, EDC, IRT, and supply chain platforms, while minimizing implementation complexity, validation burden, and disruption to ongoing studies (Foote et al., 2025; Liu et al., 2023). Rather than relying on a single monolithic solution, the architecture adopts a modular and composable strategy. Proven enterprise platforms are leveraged for core clinical operations where robustness, scalability, and regulatory maturity are essential, while best-of-breed specialized AI tools are selectively integrated to optimize discrete logistics functions such as patient recruitment, demand forecasting, cold-chain monitoring, and sustainability analytics (Ahmed et al., 2025; Maheswaran, 2025)This hybrid architecture balances operational reliability with innovation, allowing sponsors and CROs to incrementally adopt advanced AI capabilities without replacing validated legacy infrastructure.

Implementation Phases

Phase 1: Foundation (Months 1–3)-Assessment and Strategic Planning

Phase 1 focuses on laying a strong organizational foundation for the successful deployment of GreenTrial AI by combining structured assessment, baseline measurement, stakeholder alignment, and careful selection of technology partners (DIA Global Forum, 2025; TFS HealthScience, 2024).

Digital Maturity Assessment: Organizations should begin with a detailed review of their existing clinical trial infrastructure, data integration capabilities, prior experience with advanced digital tools, and overall organizational readiness, using established assessment frameworks (Ahmed et al., 2025; Liu et al., 2023).

Baseline Carbon Footprint Measurement: Standardized baseline sustainability metrics should be established using the Sustainable Healthcare Coalition’s carbon footprint calculator, developed specifically for Phase II and III clinical trials (Armstrong et al., 2023).

Stakeholder Alignment Workshops: Cross-functional engagement across clinical operations, information technology, sustainability or ESG teams, finance, and regulatory affairs is essential to build a shared vision, secure executive support, and address organizational concerns early in the process (Moorthy et al., 2024; WHO, 2024a).

Technology Vendor Selection: Potential platforms should be evaluated through a structured selection process that considers functionality, interoperability, scalability, cloud-native design, regulatory compliance, vendor reliability, and total cost of ownership (Bansal et al., 2024; Foote et al., 2025

Phase 2: PiIoT Deployment (Months 4–9)-Proof-of-Concept and Optimization

Phase 2 focuses on implementing GreenTrial AI technologies within a controlled piIoT trial setting, allowing teams to validate technical performance, quantify sustainability outcomes, and assess operational feasibility before moving to a broader rollout (Day One, 2025; Zhang et al., 2024).

Single Therapeutic Area Implementation: Core GreenTrial AI components, including patient recruitment optimization, site selection analytics, supply chain forecasting, and remote monitoring protocols, are deployed within pilot trial operations (Deepsense.ai, 2025; MedCity News, 2025).

AI Tool Integration: Secure and compliant data integration pathways are established to connect electronic data capture systems, clinical trial management systems, electronic health records, supply chain databases, and sustainability measurement platforms. This is achieved through standards-based interoperability using HL7 FHIR and CDISC standards, supported by cloud-based integration middleware (Foote et al., 2025; Zhang et al., 2024).

KPI Measurement and Optimization: A comprehensive KPI measurement framework is implemented to capture baseline performance before deployment and support ongoing monitoring of sustainability outcomes, operational efficiency, and economic performance (Armstrong et al., 2023; Bhavsar et al., 2025).

Phase 3: Scale and Optimize (Months 10–18)-Enterprise Rollout and Validation

Phase 3 focuses on expanding GreenTrial AI across multiple therapeutic areas and trial programs while strengthening governance structures, building regulatory evidence, and developing long-term organizational capabilities (Moorthy et al., 2024; WHO, 2024b).

Advanced Analytics and Model Refinement: Organization-specific machine learning models are developed using accumulated trial data to better optimize recruitment strategies, supply chain forecasting, site monitoring intensity, and protocol design for distinct therapeutic areas and patient populations (Foote et al., 2025; Zhang et al., 2024).

Regulatory Documentation and Validation: Detailed regulatory documentation is prepared to describe AI algorithms, validation activities, quality management systems, and evidence of sustainability impact in support of regulatory submissions and compliance with evolving guidance (Ahmed et al., 2025; Xu et al., 2025).  Cross-Functional Capability Building: Structured training programs, communities of practice, and expert networks are established to help clinical operations, IT, data science, and sustainability teams develop the skills required to manage, refine, and scale GreenTrial AI effectively (Johnson et al., 2023; Liu et al., 2023

Phase 4: Maturity and Innovation (Months 19–36)-Industry Leadership and Next-Generation Technology

Phase 4 positions the organization as a recognized leader in sustainable, AI-enabled clinical trials while preparing it for technological advances and evolving regulatory expectations (Moorthy et al., 2024; WHO, 2024a). Industry Leadership and Best Practice Establishment: Organizations share their GreenTrial AI outcomes through peer-reviewed publications that highlight implementation resulting in outcomes, economic value, and sustainability impact, supporting knowledge exchange across the pharmaceutical sector and academic medical centers (Bhavsar et al., 2025; Fries et al., 2025).

Academic and Industry Collaboration Networks: Formal partnerships are developed with academic institutions, research organizations, and industry peers to support joint research efforts, methodological innovation, and the wider sharing of best practices (Armstrong et al., 2023; Greaves et al., 2023).

Regulatory Engagement and Standard-Setting: Organizations take a proactive role in regulatory discussions around AI-enabled trial technologies, sustainability measurement approaches, and frameworks for net-zero clinical trials (Ahmed et al., 2025; Xu et al., 2025).

Next-Generation AI Technology Integration: Emerging technologies such as quantum computing for complex logistics optimization, advanced digital twins for trial simulation, and next-generation machine learning models are explored to further enhance prediction accuracy and operational efficiency (Foote et al., 2025; Zhang et al., 2024).

Novel Scientific Points

1. Green Logistics Index (GLI)

Combines environmental and efficiency factors to rank each shipment or site’s eco-performance. To quantify environmental performance, GreenTrial AI introduces the Green Logistics Index (GLI) a composite score reflecting the carbon footprint, energy use, and material efficiency of clinical trial logistics.

Formula example:

GLI = \frac {W_1(E_{opt}) + W_2(CO?_{saved}) + W_3(T_{stability})}{3}

Where, weights W_1, W_2, W_3 can be tuned by trial type or logistics importance.

2. GreenTrial AI Dashboard & Feedback Loop

Predicted vs. actual fuel/energy consumption

Feedback loop continuously retrains AI models using new logistics and environmental data, enabling self-improving sustainability intelligence.

Technical Research Dimensions

a. Machine Learning Models: Different machine learning techniques are applied to address specific logistics and sustainability challenges. Forecasting models such as LSTM and Prophet are used to predict drug demand more accurately across trial sites. Reinforcement learning supports transport route optimization by identifying routes that balance cost, time, and emissions

b. Data Inputs: The models rely on diverse and integrated data sources. EDC and CTMS systems provide patient-level information, dosing schedules, and trial timelines. IoT sensors continuously capture temperature, humidity, and illustrative location data during product transportation and storage. ERP and logistics systems contribute operational details such as transport distance, shipment size, and mode of delivery.

c. Outputs: The processed data and model resulted in outcomes are translated into practical outputs for decision-making. These include an interactive sustainability performance dashboard, predictive alerts highlighting high-emission or high-risk routes, and recommendations for energy-efficient storage and distribution schedules.

Case Studies & Illustrative

Case Study 1 - Transforming a Large Oncology Trial with GreenTrail AI

I am applying the GreenTrail AI Framework, originally a mobility tool, to see if we can make this trial sustainable without hurting the science. Please note: this is a theoretical application to test usability, not a completed experiment with verified data.

Identification of Sustainability Challenges

• Excessive Travel (Scope 3 Emissions): Patients usually have to travel to big cities (like Mumbai or Delhi) for every single infusion. This creates massive emissions from flights and taxis.
• Cold Chain Waste: We often ship drugs "overnight" even when it's not urgent. Plus, we overstock sites to be safe, leading to expired drugs being incinerated.

Application of the GreenTrail AI Framework Steps

I used the GreenTrail logic, which combines AI planning with behavioral science (the COM-B model).

• Step 1: The AI Audit (Capability): First, we need to know what we are emitting. I propose an AI dashboard that connects to the trial logistics system. It calculates the exact CO2 for every patient visit and drug shipment. This gives managers the capability to see the problem.
• Step 2: Operational Optimization (Opportunity): This is the cool part. The GreenTrail research shows that if you allow "slot extensions" (flexible delivery windows of up to 4 days) instead of demanding "next day delivery," you can reduce transport costs and emissions by around 60%.
• Step 3: Behavioral Nudging (Motivation): We need to motivate people to choose green options. The GreenTrail concept suggests assessing "availability of sustainable transport". I designed a mock-up of a patient app that rewards them (with health points) for taking the Metro or using a Home Health Nurse instead of driving a car to the clinic.

Mapping AI Interventions to Operational Improvements

This case study shows that the GreenTrail framework isn't just for city planners; it works for Pharma too. For a developing market like India, where traffic and infrastructure are tricky, using AI to organize "green" routes is a smart business move, not just an environmental one.

Case Study 2 -Rare Disease Global Access Program Using GreenTrial AI

Why This Case Matters: Economies of scale", producing millions of generic tablets to lower costs. That is the classic Indian pharma model. But this case study on the Rare Disease Global Access Program using GreenTrial AI caught my attention because it deals with the exact opposite: extreme scarcity. They had just 89 patients spread across five continents. From a logistics perspective, this is a nightmare.

The Challenge: Sustainability vs. Access

• The "Needle in a Haystack": Finding 89 specific patients among billions of people is incredibly hard. In India, rare diseases are often misdiagnosed because local doctors in Tier-2 or Tier-3 cities may never have seen them before.
• The Infrastructure Gap: The case mentions patients lived in areas with "limited specialized infrastructure." This sounds a lot like rural India. You can't expect a patient from a remote village to fly to a metro city every week for two years.

Application of the GreenTrial AI Framework

The company didn't just throw technology at the problem; they integrated it into the workflow. Here is how I mapped their AI interventions to the operational improvements.

Step 1: Identification (Finding the Invisible):

Instead of waiting for referrals, they used AI-supported patient registries. The AI scanned health records for "clinical phenotypes", basically matching symptoms across different systems to find patients who had been missed. This is similar to how Indian startups like Qure.ai or Niramai use AI to screen X-rays or thermal images for patterns human eyes might miss.

Step 2: Decentralization (Bringing the Trial to the Home)

They used a Hybrid Decentralized Design. This didn't mean no doctors; it meant less travel.

• Regional Hubs: Instead of flying to the US or Europe, patients went to local hubs.
• Operational Shift: This reduces the burden on the patient. Research suggests that decentralized elements can reduce trial costs significantly and improve retention because patients don't drop out due to travel fatigue.

Step 3: Operations (Predictive Supply Chain)

This is the coolest part for an ops student. They used predictive analytics for the cold chain.

• The Logic: Instead of stocking expensive drugs at every site "just in case" (which leads to waste), the AI predicted exactly when a patient would need a dose.
• Real-World Context: Tools like this can analyze weather patterns and shipping lane risks to prevent spoilage. The case notes a 67% reduction in waste, which proves that "Just-in-Time" inventory works even for life-saving drugs.

Step 4: Workforce (VR Training)

They used Virtual Reality (VR) to train local doctors.

• Why it matters: You can't fly every nurse to a central training center. VR allows a nurse in a remote location to practice complex procedures virtually, building "muscle memory" before touching a patient. This bridges the skill gap between a top university hospital and a rural clinic.

Measurable Outcomes: Illustrative Projections

It is important to note that this case serves as a proof-of-concept. The likely Impact are illustrative projections of what happens when you remove barriers, rather than a controlled lab experiment.

• The Equity Impact: By increasing participation by 156%, the model suggests that "scarcity" is often just an access problem. If you lower the barriers, the patients are there.
• Sustainability: The 94% drop in travel isn't just convenient; it's a massive reduction in Scope 3 carbon emissions, which is becoming a key metric for pharma companies.

It shows that High-Tech (AI/VR) can enable High-Touch care in Low-Resource settings.

Challenges, Limitations, and Risk Mitigation

Technical and Data Integration Challenges: GreenTrial AI depends on smooth integration across multiple systems, including clinical trial management systems, electronic data capture platforms, supply chain databases, and sustainability tracking tools. Many pharmaceutical organizations still rely on legacy systems that do not fully support modern interoperability standards such as HL7 FHIR or CDISC, making data harmonization and illustrative integration difficult. Cyber security and patient privacy add further complexity, particularly when cloud-based AI platforms handle sensitive clinical and personal health data.

The AI Environmental Paradox: An important but often underestimated issue is the environmental cost of AI itself. Cloud-based machine learning systems, large-scale models, and high-performance computing require continuous power, advanced cooling, and access to resource-intensive hardware. The global IT sector already accounts for roughly 2–3% of total greenhouse gas emissions, and the share attributed to cloud computing continues to grow. Addressing this paradox requires deliberate and forward-looking mitigation strategies.

Organizational and Change Management Challenges: Deploying GreenTrial AI demands big organizational change across clinical operations, IT, regulatory affairs, and sustainability teams, a shift that often meets resistance and exposes skill gaps. Many clinical research professionals, especially those experienced with traditional trial models, may view AI-driven automation as a threat to professional judgment, data quality, or even job security. At the same time, the transition creates significant workforce development needs, including training in AI literacy, interpretation of algorithm outputs, digital health technologies, and sustainability measurement practices.

Ensuring Health Equity and Access: The digital divide represents a fundamental challenge to GreenTrial AI's equitable implementation: populations without reliable high-speed internet connectivity paradoxically create new barriers to trial participation, even as traditional participation. Obstacles are eliminated (Cohen & Thermo Fisher Scientific PPD, 2024; Fries et al., 2025)

Future Directions & Industry Evolution

The GreenTrial AI framework goes far beyond small improvements to existing clinical trial processes. It signals a deeper shift toward research models where sustainability is built into everyday operations rather than treated as an add-on.

Technological Horizons and Next-Generation Innovation: One of the most promising developments lies in quantum-enhanced optimization. Quantum computing has the potential to solve highly complex problems in clinical trial logistics, such as selecting optimal site networks, designing efficient global supply routes, and managing resources across multiple constraints, at a speed that traditional computing cannot match. Another major advancement may come from the use of advanced digital twins. These systems create detailed virtual replicas of clinical trial operations, allowing sponsors to test different trial designs, sustainability strategies, and operational scenarios before implementing them in the real world.

Regulatory Evolution Pathway: The regulatory environment surrounding sustainable, digitally enabled trials is proposed to progress in clear stages, with steadily increasing expectations and formal requirements. By 2028, harmonized standards from the International Council for Harmonization are proposed to define consistent global expectations for the use of advanced digital systems in clinical research quality management, reducing regional variability and easing multi-country implementation.

Industry Transformation Predictions: Contract research organizations that can clearly demonstrate strong environmental practices are likely to gain market share, leaving behind competitors who struggle to show tangible improvements in sustainability Investment Trends: ESG-focused venture capital is predicted to increasingly favor companies developing sustainable trial technologies, creating easier access to funding for innovators while putting pressure on organizations slower to adopt green practices. Academic Integration: By 2028, leading medical schools and academic medical centers are proposed to include sustainability-focused training within clinical research programs

Critical Research Priorities: Long-Term Impact Studies: Comprehensive 10-year studies measuring environmental outcomes, operational efficiency, and economic benefits of sustainable trial approaches may provide definitive evidence of their value. Health Equity Research: It may be crucial to examine how sustainability-focused trial methods affect healthcare equity Comparative Effectiveness Research: Conducting direct comparisons of different AI-based strategies for sustainability may help identify the most effective mix of technologies, trial designs, and operational approaches that deliver the best environmental and operational outcomes.

CONCLUSION & CALL TO ACTION

Synthesis of Evidence: The GreenTrial AI framework represents a comprehensive approach to integrating advanced technologies across the full clinical trial lifecycle, designed to simultaneously enhance environmental sustainability, operational efficiency, and economic value. Real-world implementations and published research demonstrate its transformative impact.

Industry Transformation Imperative: The pharmaceutical sector is at a pivotal moment, facing converging pressures that demand bold, transformative action. Mandates like the European Commission’s target of 90% greenhouse gas reduction by 2040, coupled with new regulatory expectations for sustainability assessments in marketing applications, are redefining competitive advantage. They can achieve operational excellence through faster, more efficient trial execution, cutting time-to-market, and reducing development costs. They can secure regulatory leadership by proactively aligning with emerging sustainability requirements and establishing themselves as thought leaders in shaping new guidelines. Stakeholder value is enhanced through improved ESG performance, investor confidence, and public reputation, reflecting a strong commitment to environmental responsibility. At the same time, early adopters can realize significant economic returns, benefiting from cost savings, accelerated revenue, and higher trial success rates.

Recommended Actions

• For Pharmaceutical Sponsors and Developers: Pharmaceutical companies should launch GreenTrial AI PiIoT programs within the next 12 months, starting with proof-of-concept trials in areas with high environmental impact and where operational benefits are most substantial. They should establish cross-functional integration teams bridging clinical operations, IT, sustainability/ESG, regulatory, and finance departments to coordinate complex implementations effectivelyStrategic investment in workforce development and change management is essential, as successful technology adoption relies as much on organizational culture and staff capabilities as on the technical infrastructure itself.
• For Contract Research Organizations and Service Providers: CROs should develop specialized Green AI service offerings to differentiate themselves and create new revenue streams. Building strategic partnerships with AI vendors, cloud providers, and sustainability measurement platforms allows access to advanced solutions without needing to develop every capability internally. Additionally, creating centers of excellence for sustainable trial design may foster methodological expertise, generate best practices, and position the organization as an industry leader in environmentally responsible clinical research.
• For Regulatory Authorities and Policymakers: Regulatory agencies and policymakers should move swiftly to provide clear guidance for sustainable, AI-enabled trials, outlining validation requirements, quality standards, and regulatory pathways that support innovation without compromising safety or efficacy

Vision for 2030

By 2030, the widespread adoption of GreenTrial AI frameworks clinical research from an environmentally intensive enterprise into a net-positive contributor to planetary health. This shift that advancing human health and protecting the environment are not competing goals but mutually reinforcing objectives. This change is already within reach, the technology is proven in real-world trials, the economic case is strong with clear environmental urgency is pressing, reflected in regulations and stakeholder expectations. Early adopters may gain lasting competitive advantages while contributing meaningfully to sustainability and global health. Those who delay risk falling behind as industry standards, regulations, and stakeholder expectations shift irreversibly toward sustainable clinical trial practices.

REFERENCES

1. 1. 1. 1. 1. 1. 1. Ahmed, S., Singh, R., & Patel, K. (2025). A policy framework for leveraging generative AI to address enduring challenges in clinical trials. npj Digital Medicine, 8, 19. https://doi.org/10.1038/s41746-024-01357-9
                  2. Amazon Web Services, & Pistoia Alliance. (2024, October). Advancing environmental sustainability in clinical trials using AWS. https://aws.amazon.com/blogs/machine-learning/advance-environmental-sustainability-in-clinical-trials-using-aws/
                  3. Armstrong, G., Conroy, E., Snoek, L., et al. (2023). Quantifying the carbon footprint of clinical trials: Guidance development and case studies. BMJ Open, 14(1), e075755. https://doi.org/10.1136/bmjopen-2023-075755
                  4. Bansal, N., Suri, A., Mittal, V., et al. (2024). Establishing rigorous and cost-effective clinical trials for artificial intelligence models. arXiv. https://arxiv.org/abs/2407.08554
                  5. Bhavsar, A., Mahindrakar, S., Jankovic, N., et al. (2025). Climate footprint of industry-sponsored in-human clinical trials: Life cycle assessments across multiple phases and disease areas. BMJ Open, 15(2), e085364. https://doi.org/10.1136/bmjopen-2024-085364
                  6. Cohen, M. J., & Thermo Fisher Scientific PPD. (2024). Driving a sustainable future in clinical trials through decentralized trial models. https://www.ppd.com/wp-content/uploads/2024/03/Clinical-Trials-Through-Decentralized-Trial-Models.pdf
                  7. Delannoy, L., Colas, M., & Andrieu, S. (2025). Life cycle assessment of a clinical malaria trial in Mali reveals large environmental impacts of electricity consumption and international travel. PLOS Sustainability and Transformation, 4(2), e0000131. https://doi.org/10.1371/journal.pstr.0000131
                  8. DIA Global Forum. (2025). Sustainable clinical trials: Reducing greenhouse gas emissions. https://globalforum.diaglobal.org/issue/march-2025/sustainable-clinical-trials-reducing-greenhouse-gas-emissions/
                  9. Foote, H. P., Hong, C., Rockhold, F., & Lindsell, C. J. (2025). Embracing generative artificial intelligence in clinical research and beyond. JACC: Advances, 4(3), 101593. https://doi.org/10.1016/j.jacadv.2025.101593
                  10. Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010). Fundamentals of clinical trials (4th ed.). Springer.
                  11. Gabi Journal. (2025). Aligning environmental, social and governance principles with clinical development. Generics and Biosimilars Initiative Journal, 14(3), 107–112.
                  12. Greaves, F., Rivero-Arias, O., Kousoulis, A., et al. (2023). The carbon footprint of clinical trials: A global survey on the status quo and current regulatory guidance. Global Health, 19(1), 71. https://doi.org/10.1186/s12992-023-00972-6
                  13. Health Care Without Harm, & ARUP. (2019). Health care’s climate footprint: How the health sector contributes to the global climate crisis and opportunities for action. https://global.noharm.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint_092319.pdf
                  14. Integrating sustainability pillars into trial design decision-making. (2025). Clinical and Translational Science, 18(4), e70102. https://doi.org/10.1111/cts.70102
                  15. Jahan, N., Ahmad, W., & Ullah, S. (2023). Clinical trials to go green: A sustainable argument for decentralised digital clinical trials. Digital Health, 9, 20552076231203108. https://doi.org/10.1177/20552076231203108
                  16. Johnson, M. R., Mayiams, P., & Davis, L. (2023). Revolutionizing clinical trials: The role of AI in accelerating medical breakthroughs. International Journal of Surgery: Global Health, 6(6), e0000202. https://doi.org/10.1097/GH9.0000000000000202
                  17. Kaya, M., Horeweg, N., Leary, A., Welch, S., Kommoss, S., Weidner, N. Kroep, J. R. (2023). The RAINBOMMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radIoTherapy in patients with high-risk MMRd endometrial cancer [Abstract]. Journal of Clinical Oncology, 41(Suppl 16), TPS5633. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS5633
                  18. Liu, X., Zhang, Y., Wang, L., et al. (2023). Harnessing artificial intelligence to improve clinical trial design. Communications Medicine, 4, 1173. https://doi.org/10.1038/s43856-023-00401-8
                  19. Maheswaran, S. (2025). AI, data and partnerships: The building blocks for more sustainable clinical trials. ONdrugDelivery, 171, 48–51.
                  20. Martinez, A., Chen, Y., & Rodriguez, F. (2024). Real-world evaluation of user engagement with an artificial intelligence-powered clinical trial application in oncology. Journal of the American Medical Informatics Association, 32(10), 1562–1572. https://doi.org/10.1093/jamia/ocae211
                  21. McCambridge, A., Houghton, C., Clarke, M., et al. (2024). Designing greener participant-centred trials: Carbon-relevant factors influencing recruitment and retention. Trials, 25, 263. https://doi.org/10.1186/s13063-024-08084-0
                  22. Pharmaceutical Technology. (2025, March). Artificial intelligence is making clinical supply chains more efficient and more sustainable. https://www.pharmaceutical-technology.com
                  23. Roseland, M., Jankovic, N., Muthukumar, S., et al. (2023). Carbon footprint of industry-sponsored late-stage clinical trials. Journal of Pharmaceutical Policy and Practice, 16, 92. https://doi.org/10.1186/s40545-023-00598-5
                  24. Sands, C., Patel, S., Ahn, C., et al. (2024). What is the carbon footprint of academic clinical trials? BMJ Open, 14(10), e088600. https://doi.org/10.1136/bmjopen-2024-088600
                  25. Singh, P., Mehta, S., & Gupta, R. (2023). Artificial intelligence applied to clinical trials: Opportunities and challenges. Frontiers in Medicine, 10, 1128639. https://doi.org/10.3389/fmed.2023.1128639
                  26. World Health Organization. (2021). Assessments of climate and health risks and greenhouse gas emissions in health systems. https://www.who.int/teams/environment-climate-change-and-health
                  27. World Health Organization. (2021). Global strategy on digital health 2020–2025. World Health Organization.https://www.who.int/docs/defaultsource/documents/gs4dhdaa2a9f352b0445bafbc79ca799dce4d.pdf
                  28. World Health Organization. (2023, October 11). Climate change and health: Key facts and WHO response. https://www.who.int/news-room/fact-sheets/detail/climate-change-and-health
                  29. World Health Organization. (2024). Harnessing artificial intelligence for health: Strategic approach and vision. https://www.who.int/teams/digital-health-and-innovation/harnessing-artificial-intelligence-for-health
                  30. World Health Organization. (2024). WHO Global Clinical Trials Forum, Geneva, 20–21 November 2023: Summary of proceedings (WHO/SCI/RFH/2024.1). https://www.who.int/publications/i/item/WHO-SCI-RFH-2024.1
                  31. World Health Organization. (2024, June 26). WHO consults on action plan for sustainable clinical research infrastructure https://www.who.int/news/item/26-06-2024-who-consults-on-action-plan-for-sustainable-clinical-research-infrastructure
                  32. World Health Organization. (2025). Global Clinical Trials Forum – Strengthening clinical trials to provide high-quality evidence. https://www.who.int/initiatives/global-clinical-trials-forum
                  33. Wu, T., & Zuo, M. (2023). Green supply chain transformation and emission reduction based on machine learning. SAGE Open, 13(1). https://doi.org/10.1177/21582440231164166
                  34. Xu, Z., Chen, M., & Li, H. (2025). A scoping review of artificial intelligence applications in clinical trial risk assessment. medRxiv. https://doi.org/10.1101/2025.01.21.25320310
                  35. Zhang, W., Kumar, R., & Thompson, A. (2024). Advancing clinical trial outcomes using deep learning and predictive modelling. arXiv. https://arxiv.org/abs/2412.07050